-
Women with advanced epithelial ovarian cancer did not describe the treatment decision-making process as shared; rather, they described an interaction that was directed by their physician.
-
Participants in the initial Multicenter Study of Hydroxyurea in Sickle Cell Anemia interventional trial were followed, upon completion of that trial for up to 9 years, to determine the long-term effects of treatment. In this publication of the observational phase of the MSH trial, there is noted a 40% reduction in mortality for those who had received a year or more of the drug.
-
-
In a trial that included androgen-independent prostate cancer patients, 2 drug regimens were shown by randomized phase II analysis to be comparable. Both produced survival advantage when compared to prior series, including those in which mitoxantrone and prednisone were used.
-
In this series, the only prognostic factor for patients with advanced-stage borderline tumor is the type of peritoneal implant. More patients died of the treatments complications than of the disease itself.
-
Docetaxel is active in paclitaxel-resistant ovarian and peritoneal cancer, but, in view of significant hematologic toxicity, further study is warranted to ascertain its optimal dose and schedule.
-
-
Editors Note: The following reports from the annual scientific sessions of the American College of Cardiology held March 30 to April 2, 2003, were obtained by handwritten notes, press releases, and news reports.
-
-
In one of the more bizarre stories of the year, the FDA has uncovered files of counterfeit Procrit (epoetin alfaJohnson & Johnson) in routine surveillance. To make matters worse, the fake vials have been contaminated with bacteria and many contain no active ingredient.
